Home › Prostaatkanker › Californië › Orange
Prostaatkanker klinische studies in Orange, CA
14 studies voor Prostaatkanker zoeken deelnemers op locaties in en rond Orange (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
RekruterenFase 3
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
RekruterenFase 2
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
RekruterenFase 3
- University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040), Orange
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
RekruterenFase 3
- University of California Irvine, Orange
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
RekruterenFase 3
- Univ Cali Irvine ALS Neuromuscular, Orange
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
RekruterenFase 3
- University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0006), Orange
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
RekruterenFase 3
- UC Irvine Health, Orange
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
RekruterenFase 3
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
RekruterenFase 1
- UCI Health Chao Family Comprehensive Cancer Center, Orange
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
RekruterenFase 3
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RekruterenFase 2
- Chao Family Comprehensive Cancer Center, University of California Irvine, Orange
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer
RekruterenFase 1/2
- UC Irvine Medical Center, Orange
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
RekruterenFase 4
- St. Joseph Hospital, Orange
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruterenObservatieonderzoek
- Massive Bio SYNERGY-AI site, Orange
Prostaatkanker studies in andere steden
- New York City, NY103 studies
- Houston, TX76 studies
- Los Angeles, CA61 studies
- Boston, MA59 studies
- St. Louis, MO46 studies
- Chicago, IL45 studies
- San Francisco, CA45 studies
- Philadelphia, PA44 studies
- Baltimore, MD43 studies
- Nashville, TN42 studies
- Seattle, WA42 studies
- Washington, DC38 studies
Andere studies in Orange
- Niet-kleincellige longkanker25 studies
- Metastatische kanker20 studies
- Colorectale kanker16 studies
- Eierstokkanker16 studies
- Aldermeesklierkanker15 studies
- Borstkanker14 studies
- Longkanker14 studies
- Leverkanker (hepatocellulair carcinoom)14 studies
- Melanoom14 studies
- Acute myeloïde leukemie13 studies
- Kanker (alle vormen)13 studies
- Maagkanker13 studies
Van ClinicalTrials.gov, gegevens opgehaald op 5 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.